Khan Najat
CEO and President
Khan Najat has filed 10 SEC Form 4 filings (12 transaction rows) across 1 company, with disclosures dating back to 2025. 10 of those filings fall inside the rolling window. Most recent filing: Sep 10, 2026.
On the most recent filing, Khan Najat is listed as CEO and President at RECURSION PHARMACEUTICALS, INC. Inside the rolling window, Khan Najat reported no open-market purchases and 4 open-market sales totaling $807K in RXRX. The largest disclosed transaction in the window is a sale of 124,403 RXRX shares on Dec 22, 2025, worth $549K.
Companies traded
Other insiders at RXRX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$807K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Khan Najat made?
Khan Najat has filed 10 SEC Form 4 filings (12 transaction rows) across 1 company since 2025.
Which companies does Khan Najat trade?
Khan Najat has filed SEC Form 4 disclosures for 1 company, including RXRX.
When was Khan Najat's most recent SEC Form 4 filing?
Khan Najat's most recent SEC Form 4 filing on Tracefour is dated Sep 10, 2026.
What is Khan Najat's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Khan Najat is listed as CEO and President.
What is Khan Najat's total buy and sell value in the current window?
Inside the rolling retention window, Khan Najat bought $0 and sold $807K based on SEC Form 4 filings.
What was Khan Najat's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 124,403 RXRX shares on 2025-12-22, worth $549K, per SEC Form 4 filings.